AGMB Valuation

Agomab Therapeutics NV (AGMB) is now in the Fair zone, suggesting that its current forward PS ratio of NaN is considered Fairly compared with the five-year average of --. The fair price of Agomab Therapeutics NV (AGMB) is between -- to -- according to relative valuation method.

AGMB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Agomab Therapeutics NV (AGMB) is between -- to -- according to relative valuation method.

The average P/S ratio for AGMB's competitors is 1.77, providing a benchmark for relative valuation. Agomab Therapeutics NV Corp (AGMB) exhibits a P/S ratio of --, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

As of Mar 03 2026, Agomab Therapeutics NV (AGMB) has a P/B ratio of NaN. This indicates that the market values AGMB at NaN times its book value.

As of Mar 03 2026, Agomab Therapeutics NV (AGMB) has a FCF Yield of NaN%. This means that for every dollar of Agomab Therapeutics NV's market capitalization, the company generates NaN cents in free cash flow.

As of Mar 03 2026, Agomab Therapeutics NV (AGMB) has a Forward P/E ratio of NaN. This means the market is willing to pay $NaN for every dollar of Agomab Therapeutics NV's expected earnings over the next 12 months.

As of Mar 03 2026, Agomab Therapeutics NV (AGMB) has a Forward P/S ratio of NaN. This means the market is valuing AGMB at $NaN for every dollar of expected revenue over the next 12 months.